UF Scientists Eye Novel Drug Candidate With Marine Origins to Treat Vision Loss (UF Health Newsroom)

UF Scientists Eye Novel Drug Candidate With Marine Origins to Treat Vision Loss

UF College of Pharmacy researchers teamed with collaborators at SERI and at A*STAR’s Institute of Molecular and Cell Biology in Singapore, or IMCB, to see whether Apratoxin S4, a novel molecule based on marine cyanobacteria, could be an effective therapy in restricting abnormal blood vessel formation in the eye, which may be a potential treatment for these retinal diseases in the future.

“Apratoxin S4 could potentially address the resistance problem to standard-of-care VEGF therapy by inhibiting multiple new blood vessel forming pathways,” said Hendrik Luesch, Ph.D., a professor and chair of medicinal chemistry and the Debbie and Sylvia DeSantis Chair in Natural Products Drug Discovery and Development in the University of Florida’s College of Pharmacy.

Learn more about UF Scientists Eye Novel Drug Candidate With Marine Origins to Treat Vision Loss.
X